Vicore Pharma Holding AB (OSTO:VICO) Scaled Net Operating Assets: -0.06 (As of Mar. 2026)


OSTO:VICO Vicore Pharma Holding AB OSTO:VICO
28 GF Score
Price kr12.32
! 5 Warning Signs
View Full Analysis

What is Vicore Pharma Holding AB Scaled Net Operating Assets?

Vicore Pharma Holding AB OSTO:VICO +1.65% 28 Scaled Net Operating Assets is -0.06 as of Mar. 2026. GuruFocus rates OSTO:VICO with a GF Score™ of 28/100. The stock has 5 warning signs investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Vicore Pharma Holding AB's operating assets for the quarter that ended in Mar. 2026 was kr17.47 Mil. Vicore Pharma Holding AB's operating liabilities for the quarter that ended in Mar. 2026 was kr86.35 Mil. Vicore Pharma Holding AB's Total Assets for the quarter that ended in Dec. 2025 was kr1,218.64 Mil. Therefore, Vicore Pharma Holding AB's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was -0.06.

Vicore Pharma Holding AB Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Vicore Pharma Holding AB's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vicore Pharma Holding AB Scaled Net Operating Assets Chart

Vicore Pharma Holding AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.06 -0.08 -0.05 -0.06

Vicore Pharma Holding AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 -0.03 -0.04 -0.08 -0.06

OSTO:VICO vs VRTX, REGN, ALNY: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, Vicore Pharma Holding AB's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vicore Pharma Holding AB Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vicore Pharma Holding AB's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Vicore Pharma Holding AB's Scaled Net Operating Assets falls into.


OSTO:VICO
28GF Score
Vicore Pharma Holding AB OSTO:VICO
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vicore Pharma Holding AB Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Vicore Pharma Holding AB's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2025 )
=(Operating Assets (A: Dec. 2025 )-Operating Liabilities (A: Dec. 2025 ))/Total Assets (A: Dec. 2024 )
=(51.899-123.175)/1195.574
=-0.06

where

Operating Assets(A: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=1218.637 - 1166.738
=51.899

Operating Liabilities(A: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=123.175 - 0 - 0
=123.175

Vicore Pharma Holding AB's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2026 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2026 )
=(Operating Assets (Q: Mar. 2026 )-Operating Liabilities (Q: Mar. 2026 ))/Total Assets (Q: Dec. 2025 )
=(17.471-86.354)/1218.637
=-0.06

where

Operating Assets(Q: Mar. 2026 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=1077.265 - 1059.794
=17.471

Operating Liabilities(Q: Mar. 2026 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=86.354 - 0 - 0
=86.354

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of -0.06 mean?
Vicore Pharma Holding AB (OSTO:VICO) has a Scaled Net Operating Assets of -0.06 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Vicore Pharma Holding AB and its competitors.
Is Vicore Pharma Holding AB's Scaled Net Operating Assets too high?
Vicore Pharma Holding AB's current Scaled Net Operating Assets is -0.06. Overall, Vicore Pharma Holding AB has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Vicore Pharma Holding AB's Scaled Net Operating Assets compare to VRTX and REGN?
Vicore Pharma Holding AB's Scaled Net Operating Assets of -0.06 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Vicore Pharma Holding AB and its competitors. Vicore Pharma Holding AB's current Scaled Net Operating Assets is -0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vicore Pharma Holding AB stock overvalued right now?
Vicore Pharma Holding AB (OSTO:VICO) has a current Scaled Net Operating Assets of -0.06. The current Scaled Net Operating Assets is -0.06. Vicore Pharma Holding AB's overall GF Score™ is 28/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Vicore Pharma Holding AB (OSTO:VICO), the current Scaled Net Operating Assets is -0.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vicore Pharma Holding AB Business Description

Other Exchanges 6Y4:Germany
Address Kornhamnstorg 53, Stockholm, SWE, 111 27
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.
28GF Score

Get the complete analysis for OSTO:VICO

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr12.32
Price